Compare VHC & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | THAR |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 83.1M |
| IPO Year | 1999 | 2022 |
| Metric | VHC | THAR |
|---|---|---|
| Price | $22.03 | $2.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 14.6K | ★ 499.6K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2020.00 | N/A |
| 52 Week Low | $3.68 | $0.95 |
| 52 Week High | $29.00 | $9.08 |
| Indicator | VHC | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 46.50 |
| Support Level | $18.21 | $2.36 |
| Resistance Level | $23.70 | $2.55 |
| Average True Range (ATR) | 1.92 | 0.20 |
| MACD | -0.33 | 0.01 |
| Stochastic Oscillator | 56.77 | 65.60 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.